Prime Editing's First Cure: Inside the PM359 Trial That Restored a Patient's Immune System

In 2026 the genome-editing field crossed a threshold it had been approaching for years. A patient with chronic granulomatous disease — a rare, often-fatal immunodeficiency — received a single dose of an experimental therapy called PM359. The patient''s neutrophils, which had been incapable of mounting an oxidative burst to kill invading bacteria, started behaving normally. They had received the first prime-editing therapeutic ever to show clinical effect in a human.

This was a single-patient case report, not a Phase 3 readout. But the magnitude of the change — and the fact that it came from a technology that until recently lived only on lab benches — is why the trial is worth understanding in detail.

What chronic granulomatous disease is

Chronic granulomatous disease (CGD) is a group of inherited disorders in which phagocytes — primarily neutrophils — cannot generate the reactive oxygen species they normally use to kill ingested microbes. The most common form is caused by mutations in CYBB, encoding a subunit of the NADPH oxidase complex. Without that enzyme, patients suffer recurrent severe infections from organisms most immune systems would brush off.

Standard care is lifelong antimicrobial prophylaxis and immune support, with allogeneic stem cell transplant offered to patients who can find a matched donor. Both options have substantial limitations. A single corrective edit in the patient''s own hematopoietic stem cells would, in theory, fix the disease at its source. That is what PM359 is built to do.

How prime editing differs from CRISPR-Cas9

The original CRISPR-Cas9 approach makes a double-stranded break in DNA and lets the cell''s repair machinery — usually non-homologous end joining — handle the rest. That works for knocking genes out, but it is messy: you get indels, occasional translocations, and limited control over what gets inserted at the cut site.

Base editors fixed part of the problem by chemically converting one DNA letter into another without cutting both strands. They can swap C→T or A→G, but nothing else. Prime editing goes further. A prime editor is a Cas9 nickase fused to a reverse transcriptase. The guide RNA — a pegRNA — includes both a targeting sequence and an extension that encodes the desired edit. The system nicks one strand, uses the pegRNA template to synthesise the new sequence in place, and lets the cell repair the rest.

What PM359 actually does

PM359 is an ex vivo therapy. The patient''s hematopoietic stem and progenitor cells are collected, edited in the lab with a prime editor that corrects the disease-causing mutation in CYBB, and then reinfused. After conditioning, the corrected stem cells engraft and start producing neutrophils that carry the fix.

In the first dosed patient, the percentage of neutrophils with restored NADPH oxidase activity rose into a range that historical data suggests is therapeutically meaningful. Crucially, no serious adverse events related to the edit itself were reported in the initial follow-up window. The team published the data as a case report and Prime Medicine has signalled plans to expand the trial.

Why a single patient is still important

There is a sensible instinct to discount n=1 readouts. But for a rare disease with no good options and a novel mechanism, the relevant question is not statistical power. It is whether the technology does what it was designed to do in a real person. PM359''s answer is yes — at least in this patient, in this disease, with this specific edit.

The next phase of the trial expands dosing, refines the conditioning regimen, and tracks durability. Editing a long-lived stem cell population should, in principle, give a permanent fix. We don''t yet have the multi-year data to confirm that.

Where prime editing goes next

• Sickle cell and beta-thalassemia. Prime editing can install the protective HbF-promoting mutations without the indels that complicate base-editing approaches.
• Cystic fibrosis. The most common CFTR mutation (ΔF508) is a three-base deletion — exactly the kind of small indel that prime editing handles well and base editing cannot.
• Familial hypercholesterolemia. Permanent reduction of PCSK9 via prime editing is being explored as an alternative to lifelong statin therapy.
• Duchenne muscular dystrophy. Exon-skipping edits could restore partial dystrophin function in some patient subsets.

The honest caveats

Prime editing is more precise than CRISPR-Cas9, but it is not free of off-target effects. Long pegRNA templates can sometimes integrate at unintended sites. Delivery to non-blood tissues — liver, muscle, lung — is harder than ex vivo editing of stem cells. And the regulatory framework for one-shot gene therapies is still maturing, with pricing models that range from controversial to undefined.

None of that diminishes what happened in the PM359 trial. A specific genetic disease, in a specific patient, was reversed with a tool that did not exist a decade ago. The next decade is about turning that single demonstration into a treatable list.